Jubilant Life Sciences has surged 11% to Rs 381 on the BSE in an otherwise weak market after the pharmaceutical company reported 350 basis points Ebitda (earnings before interest, taxes, depreciation and amortisation) margin expansion at 26.2% for the quarter ended June 2016 (Q1FY17), up from 22.7% in the same quarter last year.
The company has reported 22% year-on-year (YoY) growth in its consolidated net profit at Rs 162 crore, despite 1.8% YoY de-growth in revenue at Rs 1,420 crore.
The management believes that the company will continue to deliver better performance going forward given the robust product pipeline in place.
On outlook, Jubilant Life Sciences said the revenue and profitability growth in pharmaceuticals segment is expected to be led by new product launches in generics with robust growth in ROW business, expected launch of Ruby-fill and strong pipeline in radiopharmaceuticals and ramp-up of operations in sterile injectables with new customer acquisitions and strong order book. Pharmaceuticals revenue is contributing 53% to the overall mix.
At 11:24 am, the stock was up 9.5% at Rs 374 on the BSE, as compared to 0.73% decline in the S&P BSE Sensex. A combined 3.45 million shares changed hands on the counter on the BSE and NSE so far.